Plasma Concentrations of Efavirenz and Nevirapine among HIV-Infected Patients with Immunological Failure Attending a Tertiary Hospital in North-Western Tanzania by Gunda, Daniel W. et al.
Plasma Concentrations of Efavirenz and Nevirapine
among HIV-Infected Patients with Immunological Failure
Attending a Tertiary Hospital in North-Western Tanzania
Daniel W. Gunda1., Christa Kasang2,3., Benson R. Kidenya4*, Rodrick Kabangila1, Stephen E. Mshana5,
Jeremiah Kidola6, Samuel E. Kalluvya1, Gilbert W. Kongola7, Hartwig Klinker8
1Department of Internal Medicine, School of Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania, 2 Institute of Virology and Immunobiology,
University of Wu¨rzburg, Wu¨rzburg, Germany, 3Medical Mission Institute, Wu¨rzburg, Germany, 4Department of Biochemistry and Molecular Biology, School of Medicine,
Catholic University of Health and Allied Sciences, Mwanza, Tanzania, 5Department of Microbiology and Immunology, School of Medicine, Catholic University of Health
and Allied Sciences, Mwanza, Tanzania, 6Mwanza Research Centre, National Institute for Medical Research (NIMR), Mwanza, Tanzania, 7Department of Clinical
Pharmacology, School of Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania, 8Division of Infectious diseases, Department of Internal Medicine,
University of Wu¨rzburg, Wu¨rzburg, Germany
Abstract
Background: Sub-therapeutic and supra-therapeutic plasma concentrations of antriretrovirals are the significant causes of
treatment failure and toxicity respectively among HIV-infected patients. We conducted this study to determine the pattern
of efavirenz and nevirapine plasma drug concentrations among adult HIV-infected patients with immunological failure
attending at a tertiary hospital in North-western Tanzania.
Materials and Methods: A cross-sectional study was conducted among adult HIV-infected patients with immunological
failure who have been on either efavirenz or nevirapine based antiretroviral regimen for more than 6 months. Patients were
serially enrolled through routine Care and Treatment Clinic (CTC) activities. Plasma drug concentrations for efavirenz and
nevirapine were determined by high performance liquid chromatography (HPLC) and Gas Chromatography (GC)
respectively. Demographic, clinical and laboratory data such as viral load and CD4 counts were collected. Data analysis was
done using STATA 12.
Results: Of the 152 patients with immunological failure enrolled, the sub-therapeutic, therapeutic and supra-therapeutic
plasma antiretroviral drug concentrations were found in 43/152 (28.3%), 76/152 (50.0%) and 33/152 (21.7%) respectively.
Half of the patients were outside therapeutic window with either sub-therapeutic or supra-therapeutic plasma ARV drug
concentrations. There was a significant difference in distribution of ARV adherence (p-value,0.001), NRTI backbone (p-
value = 0.039), HIV stage (p-value = 0.026) and viral load (p-value = 0.007) within sub-therapeutic, therapeutic and supra-
therapeutic ARV plasma drug concentrations.
Conclusion: There is a wide inter-individual variability of plasma ARV concentrations among HIV patients with
immunological failure, with a large proportion of patients being outside therapeutic window. This variability is significant
based on ARV adherence, NRTI backbone, viral load and HIV stage. Routine therapeutic drug monitoring (TDM) could assist
identifying these patients early and making timely correction to avoid virological failure, poor immunological outcome and
prevent associated drug toxicities. Nonetheless, ARV adherence should be strictly emphasized on HIV patients with
immunological failure.
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Introduction
The primary aim of antiretroviral therapy (ART) is to durably
suppress the viral replication to undetectable levels to allow a
satisfactory immune recovery [1,2]. This is achieved by a long
term use of ART at therapeutic concentrations [3]. An exposure of
the virus at sub-therapeutic concentrations is likely to cause
insufficient suppression of the virus and a probable selection of the
resistant strains which will ultimately reduce the efficacy and
durability of the ART [4]. Despite the overall success of ART, still
many areas are reporting an inadequate virological suppression
and drug toxicity complications [5]. The sub-therapeutic ART
concentrations stand to be the main cause of poor therapeutic
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outcome [6–12]. On the other hand supra-therapeutic concen-
trations of ART are frequently associated with toxicities. Previous
studies have indicated that between 30–40% of the patients
assumed to have drug-related toxicities have abnormally high
plasma concentrations of ARTs [4,6,13–17].
Efavirenz and nevirapine are the core and first line non-
nucleoside reverse transcriptase inhibitors (NNRTI) commonly
used to treat HIV infection [17–19]. Therapeutic drug monitoring
(TDM) in patients on ART including these agents has suggested
being beneficial in terms of efficacy and toxicity [17,18]. TDM is
an approach by which the course of therapy for a patient is guided
by measurements of plasma drug concentrations enabling
physicians to optimize ART drug effectiveness and to avoid
drug-related toxicity [4,20,21]. A number of studies have
documented a better treatment outcome in patients whose
treatment was TDM guided than those whose concentrations
were not monitored [22,23]. In this regard TDM is useful in
assessing adherence, investigating drug-drug interactions between
antiretroviral drugs or with co-medications, preventing some ART
drug toxicities, adjusting the dosage in particular populations, and
increasing ART efficacy of some drugs in naive patients
[4,9,12,20,22,24]. TDM of ART agents could also be useful in
provision of timely dosage adjustments to avoid drug sub-
therapeutic or toxic concentrations [12,22,25]. Despite this fact
TDM is not done in our setting and therefore the proportions of
adult HIV patients with sub-therapeutic, therapeutic and supra-
therapeutic ARV plasma concentrations are not known. Therefore
it was the aim of this study to determine the pattern of plasma
concentrations of the commonly used ART regimens containing
efavirenz and nevirapine, among adult HIV-infected patients with
immunological failure.
Materials and Methods
Study design and setting
This was a hospital based cross-sectional study which was
conducted between April 2011 and March 2012 at Bugando
Medical Centre (BMC) at Care and Treatment Center (CTC) in
Mwanza, Tanzania. BMC is a 1000-bed capacity, tertiary and
teaching hospital for the North Western Tanzania. The hospital
serves around 13 million people and CTC activities is one of the
core part of outpatient activities, which started in 2004, and
currently it serves more than 10,000 patients, of whom about
3,600 are active on ARTs. The permission to conduct this study
was obtained from the Catholic University of Health and Allied
Sciences (CUHAS)/BMC joint ethics review board. The written
consent was obtained from all participants.
Study population, patients’ enrolment and data
collection
The study population was adult HIV patients on either
efavirenz or nevirapine based regimen for more than 6 months
with immunological failure attending BMC CTC. All patients
were treated with the standard dose of nevirapine 200 mg twicw
daily and efavirenz 600 mg once daily. Inclusion criteria were
adult HIV positive patients diagnosed as per WHO guidelines, age
over 18 years with immunological failure as per WHO guideline
and still on first line. Pregnant women and patients co-treated with
anti-tuberculosis medications and other concomitant medications
known to interact with NNRTI [26] were excluded.
Immunological failure was diagnosed if the patient met one of
the following criteria: i) persistent CD4 below 100 cells/mm3, ii) a
drop of CD4 cell count below baseline pre-treatment level, or iii) a
drop of CD4 cell count of 50% from peak on treatment value all in
the absence of an ongoing co-infection and after a minimum of 6
months of ART. For criteria ii and iii, the CD4 cell count must
also fall below 200 cells/mm3 to qualify as immunologic failure
[27]. After giving consent a structured questionnaire was used to
collect information regarding demographic data, body mass index
(BMI), date of diagnosis of HIV, date of ART initiation, regime
and adherence. ART adherence level in the last 30 days was
assessed using pill counts [28]. The pill counts were performed by
the study pharmacist, who counted the number of remaining pills
at each drug refill visit. Pill count-based adherence was assessed
using the formula [Adherence = (Number of pills dispensed -
Number of pills returned) 6100)/(Number of pills prescribed
daily6Number of days between pharmacy visits)]. Good adher-
ence was defined as a value $95% pills whereas poor adherence
was defined as a value ,95%. The patients were instructed to
have their medication at night and come the following morning for
blood sample collection before taking their next ART dose. Two
blood samples were drawn, one for viral load which was done at
BMC main laboratory and the other sample was sent to Germany
for TDM to determine the plasma concentrations of efavirenz and
nevirapine.
Sample collection, processing and analysis
Patients were instructed to have medication at night and come
the following morning for blood sample collection before taking
their next ART dose to determine their antiretroviral plasmatic
trough concentrations for nevirapine and the mid concentrations
for efavirenz. For each patient, 5 ml of whole blood was collected
in plasma EDTA bottles for TDM, approximately 8 to 12 hours
after the last dose of ART, just before the next dose was due. The
samples were immediately centrifuged at 3000 rpm for 3 minutes
to obtain plasma that was transferred into cryovials. The cryovials
were stored at 220uC before shipment. The samples were packed
and shipped to Germany in cold boxes with cooling packs
maintaining a temperature of 230uC. The plasma concentrations
of efavirenz (EFV) and nevirapine (NVP) were determined using
High Performance Liquid Chromatography (HPLC) [HPLC
Beckman Coulter System Gold] and Gas Chromatography (GC)
[GC 6890; Agilent Technology] respectively as described previ-
ously [29,30]. The well-established HPLC/GC method used in
this study to determine plasma concentrations of non-nucleoside
reverse transcriptase inhibitors (NNRTI) is highly specific and
sensitive. The limit of detection (LOD) of nevirapine was
determined at 2 ng/ml, the lower limit of quantification (LLQ)
of nevirapine was reached at a concentration of 10 ng/ml. For
efavirenz the LOD was 3 ng/ml, and the LLQ was 25 ng/ml.
Additional 5 ml of whole blood was collected in a tube
supplemented with EDTA (BD Biosciences) for plasma prepara-
tion and sent to BMC main laboratory for viral load analysis using
COBAS AmpliPrep/COBAS TaqMan (Roche molecular systems,
USA) according to manufacturer’s guidelines as described
previously [31].
Data management and analysis
Data were managed using Epi Data 3.1 (CDC Atlanta, US) and
analysis was done using STATA version 12 (College Station,
Texas, US). ARV drug concentrations were recorded as contin-
uous variables. Based on the reference ARVs therapeutic ranges,
defined as 1000–4000 ng/ml for EFV and 3400–8000 ng/ml for
NVP [12], we defined 3 categories of ARV plasma drug
concentrations: sub-therapeutic (below the lower therapeutic range
limit), therapeutic (within the therapeutic range), and supra-
therapeutic (above the higher therapeutic ranged limit) [12].
Categorical variables were summarized as proportion and their
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significance of the difference in distribution within the categories
of ARV plasma drug concentrations was assessed using Pearson’s
Chi-square test or Fisher’s exact test where appropriate. We used
probability plots and Shapiro-Wilk normality test to assess the
normality of continuous variables. Parametric continuous data
were summarized as mean with standard deviation and the
significance of difference in means within categories of ARV
plasma drug concentrations was assessed using one way analysis of
variance (ANOVA). Non-parametric continuous data were
summarized as median with interquartile range and the difference
in medians within the categories of ARV plasma drug concentra-
tions was compared using Kruskal-Wallis equality-of-populations
rank test. Inter-individual pharmacokinetic variability was evalu-
ated through the coefficient of variation calculated as the quotient
of the standard deviation divided by the mean plasma drug
concentrations 6100. In determining the median and the inter-
individual pharmacokinetic variability, patients with plasma drug
concentrations below the lower limit of quantification of the assay
(25 ng/ml and 10 ng/ml for efavirenz and nevirapine respectively)
were arbitrarily considered as having a level of 24 ng/ml for
efavirenz and 9 ng/ml for nevirapine. In all analyses the difference
was considered significant if a p-value was less than 0.05.
Results
A total of 152 HIV infected adult patients with immunological
failure were enrolled in the study. Of these 79/152 (52.0%) were
using nevirapine based regimen whereas 73/152 (48.0%) were on
efavirenz based regimen. The ART regimens used were
Zidovudine+Lamivudine+Nevirapine 46/152 (30.3%), Zidovudi-
ne+Lamivudine+Efavirenz 45/152 (29.6%), Stavudine+Lamivu-
dine+Nevirapine 31/152 (20.4%), Tenofovir+Emtricitabine+Efa-
virenz 28/152 (18.4%) and Tenofovir+Emtricitabine+Nevirapine
2/152 (1.3%). The duration of use of these regimens ranged from
7 to 72 months. The mean age was 40.8610.0 years with most
patients 107/152 (70.4%) being females (Table 1). Of the 152
patients with immunological failure, 121/152 (79.6%) were in
WHO clinical stage 2 or 3. Good adherence was observed in
84.2% (128/152) of patients while a viral load $400 copies/ ml
was observed in 44.7% (68/152). There were 8/152 (5.3%)
patients co-infected with either hepatitis B or C virus (HBV or
HCV) infection, of these 7 had HBV and one had HBC. The
median [interquartile range] plasma concentrations of efavirenz
and nevirapine were 2112 [1349–3452] ng/ml and 4915 [2326–
7044] ng/ml respectively (Table 1).
Of the 152 patients enrolled, the sub-therapeutic, therapeutic
and supra-therapeutic plasma antiretroviral drug concentrations
were observed in 43/152 (28.3%), 76/152 (50.0%) and 33/152
(21.7%) respectively. Half of the patients were outside therapeutic
window with either sub-therapeutic or supra-therapeutic plasma
ARV drug concentrations. Based on the ARV regimens, sub-
therapeutic plasma concentrations were more common among
patients using nevirapine than those using efavirenz, 35.4% (28/
79) versus 20.5% (15/73). Supra-therapeutic plasma antiretroviral
drug concentrations were slightly lower among patients using
nevirapine than those using efavirenz, 20.3% 16/79 versus 23.3%
(17/73). These differences were not statistically significant
(Table 2). Of the 43 patients with sub-therapeutic plasma
antiretroviral drug concentrations, 17 (39.5%) had concentrations
below the detection limit of the HPLC/GC. Of these, 12 were
using efavirenz and 5 were using nevirapine.
Sub-therapeutic drug concentrations were significantly more
common (as supra-therapeutic was less common) among patients
with poor ARV adherence, NRTI backbone comprising Stavudi-
ne+Lamivudine (d4T+3TC), advanced HIV stage and those with
high viral loads than their counterparts. Generally, there was a
significant difference in distribution of ARV adherence rate (p-
value,0.001), type of NRTI backobone (p-value = 0.039), viral
load (p-value = 0.007) and WHO HIV stage (p-value = 0.026)
within the categories of ARV plasma drug concentrations (sub-
therapeutic, therapeutic and supra-therapeutic). Table 2 summa-
rizes the significance of the difference in distribution of various
patients’ characteristics within the categories of ARV plasma drug
concentrations. The inter-individual variability was higher among
patients using efavirenz based therapy than those using nevirapine
based therapy (120.9% versus 88.7%). Generally, there was a wide
inter-individual variability of plasma ARV concentrations among
HIV patients with immunological failure using efavirenz and
nevirapine in routine clinical practice as summarized in table 3.
Discussion
This study has demonstrated a presence of a wide inter-
individual variability of plasma ARV concentrations among HIV
patients with immunological failure in routine clinical practice,
with a large proportion of patients being outside therapeutic
window. This emphasizes that clinicians are often confronted with
treatment failure or side-effects, and are in need of methods to
evaluate drug exposure among these patients. The finding of
higher inter-individual variability among patients using efavirenz
based therapy than those using nevirapine based therapy was also
observed in a study done in Italy [32]. However, our inter-
individual variability was higher than that observed in Italy for
both antiretroviral drugs (120.9% and 88.7% versus 85.1% and
50.1% respectively) [32].
In this study sub-therapeutic ARV plasma concentrations were
detected in 28.3% of patients. Our findings are similar to that
obtained in the study done in Netherlands among patients at a risk
of treatment failure in a routine clinical care, in which 27.4% of
the plasma concentrations were classified as having sub-therapeu-
tic ARV plasma concentrations [21]. However, our findings are
slightly higher than that from previous studies done in Uganda and
Italy, in which the overall sub-therapeutic ARV concentrations
were found in 14.3% and 16.9% respectively [33,34]. This
difference in prevalence might be due to the fact that in our study
all participants had immunological failure, which was not the case
in the Ugandan and Italian studies. Furthermore, our prevalence
of sub-therapeutic ARV are lower than that from a study done
British Columbia, in which the overall sub-therapeutic ARV
concentrations were reported in 41.8% of patients with immuno-
logical failure [35]. This high prevalence could be attributed by
the fact that all participants in the British Columbian study had a
CD4 cell count less than 50 cells/ ml. On the other hand, supra-
therapeutic ARV plasma concentrations were detected in 21.7%
of patients. This prevalence is comparable to that reported from
Uganda where 23.9% of the patients had supra-therapeutic ARV
plasma concentrations [33], nevertheless all these observations
embrace comparable consequence [17,20] in clinical practice of
HIV medicine.
The observations from this study are of paramount clinical
relevance especially in resource-limited setting like ours. For the
first time in Tanzania, we have demonstrated a presence of a wide
inter-individual variability of plasma ARV concentrations and a
significant association between good adherence and therapeutic
ARV plasma concentrations among HIV-infected patients with
immunological failure. We found that the proportion of patients
with sub-therapeutic ARV plasma concentrations significantly
increased with poor ART adherence, NRTI backbone comprising
Efavirenz and Nevirapine Levels in HIV Patients
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Stavudine+Lamivudine (d4T+3TC), increasing viral loads and
advancing HIV stage. This finding is similar to that from previous
studies done in Uganda and Italy [33,34].
Therapeutic drug concentrations are a key to successful ART
[7,36], as any low drug concentrations observed in patients on
ART has been extrapolative of a failure to achieve an immediate
virological success and a longer term immunological failure
[31,37]. We found that the proportion of patients with sub-
therapeutic ARV plasma concentrations was significantly high in
patients with high viral loads ($400copies/ ml) than those with low
Table 1. Distribution of patients’ characteristics among 152 participants.
Patient Characteristic Number (%)/Mean±SD/Median [IQR]*
Antiretroviral based regimen
Efavirenz 73 (48.0)
Nevirapine 79 (52.0)
Mean age in years 40610.0
Gender
Female 107 (70.4)
Males 45 (29.6)
Median BMI in Kg/M2 22.2 [20.5–24.8]
Median antiretroviral concentrations (ng/ml)
Efavirenz 2112 [1349–3452]
Nevirapine 4915 [2326–7044]
NRTI backbone
AZT+3TC 91 (59.9)
D4T+3TC 31 (20.4)
TDF+FTC 30 (19.7)
Median Duration on ART in months 40 [26–48]
ARV Adherence level
Good 128 (84.2)
Poor 24 (15.8)
Median Enrolment CD4 counts (cell/ ml) 200 [133–288]
Viral Load (copies/ ml)
$400 68 (44.7)
,400 84 (55.3)
WHO HIV stage
Stage 1 11 (7.2)
Stage 2 63 (41.4)
Stage 3 58 (38.2)
Stage 4 20 (13.2)
Hepatitis B/C virus co-infection
No 8 (5.3)
Yes 144 (94.7)
Plasma ARV Drug level
Sub-therapeutic 43 (28.3)
Therapeutic 76 (50.0)
Supra-therapeutic 33 (21.7)
*SD= Standard deviation; IQR = Interquartile range; CD4=Cluster of differentiation; BMI = Body mass index; ARV =Antiretroviral; AZT=Azidothymidine (Zidovudine);
3TC = Lamivudine; TDF= Tenofovir; FTC = Emitricitabine; D4T = Stavudine.
doi:10.1371/journal.pone.0075118.t001
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viral loads (,400copies/ ml) [39.7% versus 19.0%]. The presence
of high rates of sub-therapeutic ARV concentrations among adult
patients implies that these patients are standing a high risk of
inadequate viral suppression and a subsequent potential of
developing and accumulating resistant viral strains [4,38], if these
drug concentrations are not corrected timely [39]. On the other
hand the patients with supra-therapeutic plasma NNRTI, are at a
high risk of developing drug toxicity [16-18] which has also been
Table 2. Comparison of distribution of patients’ characteristics within plasma antiretroviral drug concentrations (sub-therapeutic,
therapeutic and supra-therapeutic) among 152 participants.
PATIENT CHARACTERISTIC PLASMA DRUG CONCENTRATIONS p-value
SUB-THERAPEUTIC THERAPEUTIC SUPRA-THERAPEUTIC
n=43 n=76 n=33
Antiretroviral based regimen
Efavirenz 15 (20.5) 41 (56.2) 17 (23.3) 0.122
Nevirapine 28 (35.4) 35 (44.3) 16 (20.3)
Mean Age (years) 38.3610.4 40.869.7 44.069.8 0.053
Gender
Female 34 (31.8) 50 (46.7) 23 (21.5) 0.311
Male 9 (20.0) 26 (57.8) 10 (22.2)
Median BMI (Kg/M2) 22.9 [21.1–27.2] 22.1 [20.6–24.6] 21.6 [19.0–24.2] 0.299
NRTI backbone
AZT+3TC 22 (24.2) 48 (52.7) 21 (23.1) 0.039
D4T+3TC 15 (48.4) 9 (29.0) 7 (22.6)
TDF+FTC 6 (20.0) 19 (63.3) 5 (16.7)
Median ART duration (months) 36 [24–48] 39 [27–48] 45 [33–48] 0.535
ART Adherence
Good 26 (20.3) 70 (54.7) 32 (25.0) ,0.001
Poor 17 (70.8) 6 (25.0) 1 (4.2)
Viral Load (copies/ ml)
,400 16 (19.0) 44 (52.4) 24 (28.6) 0.007
$400 27 (39.7) 32 (47.1) 9 (13.2)
WHO HIV Stage
Stage 1 or 2 18 (24.3) 45 (60.8) 11 (14.9) 0.026
Stage 3 or 4 25 (32.1) 31 (39.7) 22 (28.2)
Hepatitis B/C virus co-infection
No 39 (27.1) 73 (50.7) 32 (22.2) 0.399
Yes 4 (50.0) 3 (37.5) 1 (12.5)
*NRTI = Nucleoside reverse transcriptase inhibitor, ARV =Antiretroviral; BMI = Body Mass Index; AZT=Azidothymidine (Zidovudine); 3TC = Lamivudine; TDF= Tenofovir;
FTC = Emitricitabine; D4T = Stavudine.
doi:10.1371/journal.pone.0075118.t002
Table 3. Inter-individual variability for Efavirenz and Nevirapine among 152 participants.
Antiretroviral drug Number of patients
Mean plasmatic drug concentrations±SD in
ng/ml Inter-individual Coefficient of variation (%)
Efavirenz 73 3539.264831.5 120.9
Nevirapine 79 5448.764831.5 88.7
*SD= Standard Deviation
doi:10.1371/journal.pone.0075118.t003
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reported as a common cause of non-compliance and discontinu-
ation of their medications [6,14]. Moreover it is well documented
that drug toxicity happens commonly among patients with supra-
therapeutic than among those with normal drug (therapeutic)
concentrations [4,6,13,14,16,17]. In this study 13.2% of patients
with supra-therapeutic plasma drug concentrations also had high
viral loads. This minor proportion of patients with supra-
therapeutic and yet had high viral loads might be harboring
HIV drug resistant strains. So both sub-therapeutic and supra-
therapeutic ARV concentrations are clinically very important in
the current era of HIV medicine. However this is a great challenge
in Tanzania and other resource-limited settings where TDM is not
done. Therefore, it is difficult to diagnose patients with sub-
therapeutic and supra-therapeutic ARV status in order to make
appropriate corrections to improve virological outcome of our
patients. Since this study has demonstrated that a good adherence
among patients with immunological failure is significantly
associated with therapeutic ARV plasma level, strict emphasis
on ARV adherence on this study population could be very helpful.
Conclusion
There is a wide inter-individual variability of plasma ARV
concentrations among HIV patients with immunological failure in
routine clinical practice, with a large proportion of patients being
outside therapeutic window. This variability is associated with
ARV adherence, NRTI backbone, viral load and HIV stage.
Routine therapeutic drug monitoring (TDM) could assist identi-
fying these patients early and making timely correction to avoid
immediate virological failure, long term poor immunological
outcome and prevent associated drug toxicities. Good adherence is
associated with therapeutic ARV plasma concentrations; therefore
ARV adherence should be strictly emphasized on HIV patients
with immunological failure.
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